Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Abstract
Introduction: Pancreatic adenocarcinoma is now the third-leading cause of cancer-related deaths in the US which can be attributed to rising incidence, diagnosis at advanced stages and early development of metastasis. Systemic therapy remains palliative with early development of resistance possibly related to the constitutive activation of ‘undruggable’ KRAS, immunosuppressive microenvironment, and intense desmoplasia. The advancements in...
Paper Details
Title
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Published Date
Apr 3, 2021
Volume
26
Issue
2
Pages
103 - 129
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History